MOR 107
Alternative Names: LP 2; LP2-3; MOR107Latest Information Update: 25 Jul 2024
At a glance
- Originator Lanthio Pharma
- Developer Lanthio Pharma; MorphoSys
- Class Antifibrotics; Antineoplastics; Peptides
- Mechanism of Action Angiotensin type 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Diabetic nephropathies; Fibrosis
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in Germany
- 28 Jul 2020 Discontinued - Phase-I for Diabetic nephropathies (In volunteers) in United Kingdom (SC) (Morphosys pipeline July 2020)
- 28 Jul 2020 Discontinued - Phase-I for Fibrosis (In volunteers) in United Kingdom (SC) (Morphosys pipeline July 2020)